	US 12,350,331 B2
	Bivalent dengue/hepatitus B vaccines
Daniel H. Libraty, Newton, MA (US)
Assigned to UNIVERSITY OF MASSACHUSETTS, Westborough, MA (US)
Filed by UNIVERSITY OF MASSACHUSETTS, Boston, MA (US)
Filed on Sep. 21, 2023, as Appl. No. 18/471,955.
Application 18/471,955 is a continuation of application No. 16/612,152, granted, now 11,793,873, previously published as PCT/US2018/030542, filed on May 1, 2018.
Claims priority of provisional application 62/504,188, filed on May 10, 2017.
Prior Publication US 2024/0123062 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61K 39/295 (2006.01); A61K 47/65 (2017.01); A61P 31/14 (2006.01); A61P 31/20 (2006.01)

CPC A61K 39/295 (2013.01) [A61K 39/12 (2013.01); A61K 39/292 (2013.01); A61K 47/65 (2017.08); A61P 31/14 (2018.01); A61P 31/20 (2018.01)]

20 Claims

1. A method, comprising:

a) providing;

i) a mammal in need of a broad spectrum viral vaccination; and

ii) a bivalent vaccine peptide comprising a first conserved dengue antigenic envelope peptide located in a fusion loop that is adjacent to a second conserved dengue antigenic envelope peptide that resides in a bc loop; and

b) immunizing said mammal with said bivalent vaccine peptide such that:

i) viral-infection protective levels of neutralizing polyclonal antibodies to said first conserved dengue antigenic envelope peptide and neutralizing antibodies to said second conserved dengue antigenic envelope peptide are produced; and

ii) clinically ineffective levels of enhancing antibodies to said first dengue antigenic envelope peptide antibodies and enhancing antibodies to said second dengue antigenic envelope peptide antibodies are produced.